精彩推荐:青光眼 白内障 近视 远视 散光 斜视弱视 角膜溃疡 角膜炎 沙眼 眼外伤 更多疾病
大众频道
专业频道
时尚频道
互动频道
疾 病 | 保 健 | 爱眼动态 | 名医名院
知 识 | 美 食 | 自检自测 | 爱眼纪事
资 讯 | 临 床 | 学 术 | 文 献
图 谱 | 医 患 | 继 教 | 家 园
五官之美 | 整 形 | 美 容
眼镜一族 | 妆 容 | 图 库
眼科在线 | 预留位置
眼科知道 | 在线咨询
  当前位置:当前位置: 中华眼科在线 → 医学频道 → 文献 → 正文 切换到繁體中文 用户登录 新用户注册
玻璃体内的贝伐单抗治疗中心凹下特发性脉络膜新生血管化:为期1年的预期试验结果

http://www.cnophol.com 2012-4-18 10:59:54 中华眼科在线

  摘要:PURPOSE: To evaluate the visual and anatomic outcomes of intravitreal bevacizumab in patients with subfoveal idiopathic choroidal neovascularization (CNV).

  内容:PURPOSE: To evaluate the visual and anatomic outcomes of intravitreal bevacizumab in patients with subfoveal idiopathic choroidal neovascularization (CNV).

  DESIGN: Prospective, nonrandomized, interventional case series.

  METHODS: Forty patients with subfoveal idiopathic CNV were included in this clinical trial. Their eyes were treated with a single intravitreal injection of 1.25 mg bevacizumab followed by as-needed dosing indicated by the presence and recurrence of intraretinal edema, subretinal fluid (SRF), or pigment epithelial detachment (PED), based on optical coherence tomography (OCT) performed monthly. Visual, clinical, angiographic, and anatomic changes were observed over a 12-month follow-up period.

  RESULTS: After 12 months of follow-up, the mean logarithm of minimal angle of resolution (logMAR) best-corrected visual acuity (BCVA) improved from 0.53 (20/68 in Snellen equivalent) at baseline to 0.29 (20/39 in Snellen equivalent; P < .001). Mean central retinal thickness determined by OCT decreased from 321 mum to 237 mum (P < .001). All eyes (100%) had stable or improved vision, and 28 eyes (70%) showed an improvement of 2 lines or more. All lesions were in the cicatricial stage of CNV at 12 months of follow-up, with no leakage of fluorescein in the late phase of fluorescein angiography and no intraretinal edema, SRF, and/or PED detected by OCT. No drug-related systemic or ocular side effects were observed.

  CONCLUSIONS: Intravitreal bevacizumab is generally well tolerated and improves BCVA in eyes with subfoveal idiopathic CNV over a period of 12 months. Large, randomized, controlled, long-term clinical trials are required to further evaluate the efficacy and optimal strategy of this treatment modality.

  关键词:玻璃 体内 治疗

  作 者: Zhang H, Liu ZL, Sun P, et al

  刊名: American Journal of Ophthalmology

  出版年:2012

  页码:Am J Ophthalmol. 2012. 153(2):300-306.e1

(来源:典必殊网) (责编:xhhdm)

发表评论】【加入收藏】【告诉好友】【打印此文】【关闭窗口
  • 下一条信息: 没有了
  • 更多关于(视网膜,厚度)的信息
      热门图文

    黑眼圈暴露你的健康问

    妆容粉色当红春季唯美

    白领最应该学习的紧致

    眼部按摩诀窍 彻底消除
      健康新看点
      健康多视点
    ad推广
      图话健康
    点击申请点击申请点击申请点击申请点击申请点击申请点击申请
    华夏近视网39健康网眼病中国眼镜网新浪福建健康21世纪药店网千龙求医查疾病114个性导航眼科时讯中华网健康频道国家健康网
    眼科新闻医脉通眼科中国风湿网蓝莓眼科网中国眼科网39五官科中华碑林医学网整形美容英智眼科中国眼网

    Copyright © 2007 中华眼科在线 网站备案序列号: 京ICP备08009675号
    本网站由五景药业主办 北京金鼎盛世医学传媒机构负责运营 国家医学教育发展中心提供学术支持
    服务电话:010-63330565 服务邮箱: [email protected]